Clinical Trial

Intestinal Tissue-Resident Memory T Cells and HIV-1 Persistence During Antiretroviral Therapy

Study acronym: ANRSGALT-2
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The study aims to better characterize intestinal tissue-resident memory T cells (TRM) in people living with HIV-1 receiving suppressive antiretroviral therapy (ART). TRM cells are key components of tissue immunity and may contribute to HIV-1 persistence within the intestinal mucosa, a major viral reservoir. The phenotypic, transcriptomic, and functional characteristics of intestinal CD4+ and CD8+ TRM cells, their susceptibility to HIV-1 infection, and their potential role as viral reservoirs will be investigated. Blood samples and additional colonic biopsies obtained during routine clinically indicated colonoscopy will be collected from HIV-1-infected participants and HIV-seronegative controls.
Trial Details
NCT Number NCT07656077
Lead Sponsor ANRS, Emerging Infectious Diseases
Conditions HIV-1 Infection, HIV Reservoir, Antiretroviral Therapy
Enrollment 30 participants
Start Date 2026-08-01
Primary Completion 2028-07-31 (estimated)
Study Completion 2030-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-18